-The annual production capacity of ritonavir oral tablets has been expanded to 100 million tablets, and can be further rapidly expanded according to market demand
-ASC10 is an oral direct-acting antiviral drug candidate that targets RNA-dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
-ASC11 is an oral direct-acting antiviral drug candidate, targeting 3-chymotrypsin-like protease (3CLpro), combined with ritonavir oral tablets, for the treatment of SARS-CoV-2 infection
Hangzhou Shaoxing China, January 2, 2022 /PRNewswire/- Ascletis Pharma Inc. (HKEX: 1672) today announced the expansion of the production of ritonavir oral tablets and the R&D pipeline of oral direct-acting antiviral drugs for the treatment of SARS-CoV-2 infection.The company’s COVID-19 pipeline currently includes (i) oral ritonavir pill (100 mg), A licensed product, (ii) ASC10, an oral RNA-dependent RNA polymerase (RdRp) inhibitor and (iii) ASC11, an oral 3-chymotrypsin-like protease (3CLpro) inhibitor.
The company has the only authorized ritonavir oral tablet in China China, Passed the bioequivalence study. The company’s ritonavir oral tablets were approved by the National Medical Products Administration (NMPA) of China in September 2021. As a pharmacokinetic enhancer for a variety of antiviral protease inhibitors, low dose…
